| Clime Investment Management Ltd (CIW) ORDINARY FULLY PAID |
Financials |
$26 |
Sale of Clime International Fund
|
26 Feb 2026 10:04AM |
$0.365 |
$0.315 |
fallen by
13.70%
|
|
CIW - Price-sensitive ASX Announcement
Full Release
Key Points
- Clime entered an agreement to sell the Clime International Fund.
- The transaction is worth $2 million payable in cash tranches.
- Clime will continue as Investment Manager until the purchaser launches in Australia.
- The purchaser's identity is confidential pending trustee consent.
- Settlement expected before 30 March 2026.
- The sale aligns with Clime's strategy to streamline and focus on wholesale business.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| QBE Insurance Group Limited (QBE) ORDINARY FULLY PAID |
Financials |
$34,422 |
Change of Director's Interest Notice
|
26 Feb 2026 10:01AM |
$21.890 |
$23.040 |
risen by
5.25%
|
|
| Newmont Corporation (NEM) CDI 1:1 FOREIGN EXEMPT NYSE |
Materials |
$168,840 |
Form 144 as filed - Mark Rodgers
|
26 Feb 2026 10:01AM |
$174.540 |
$157.440 |
fallen by
9.80%
|
|
| CIMIC Group Limited (CIM) ORDINARY FULLY PAID |
Industrials |
- |
Challenger IM Monthly Report January
|
26 Feb 2026 10:00AM |
$22.000 |
$22.000 |
fallen by
0%
|
|
| Alexium International Group Limited (AJX) ORDINARY FULLY PAID |
Materials |
$22 |
Alexium1H26 Results Presentation
|
26 Feb 2026 10:00AM |
$0.007 |
$0.007 |
fallen by
0%
|
|
| Pure Foods Tasmania Limited (PFT) ORDINARY FULLY PAID |
Consumer Staple |
$7 |
Easter trading update and ranging with Costco
|
26 Feb 2026 10:00AM |
$0.029 |
$0.023 |
fallen by
20.69%
|
|
PFT - Price-sensitive ASX Announcement
Full Release
Key Points
- Easter orders for Tasmanian Pâté increased 71% year-on-year.
- Approximately $150,000 additional revenue from Easter period.
- New product ranging secured with Costco Australia.
- Initial Costco products include 300g Pâté SKU and 1kg Daly Potato bags.
- Products scheduled to be on shelves from March 16, 2026.
- Initial eight-week Costco program expected to generate $150,000 in revenue.
- Combined revenue growth from Easter and Costco expected to be $300,000.
- Opportunity to expand range and shelf presence subject to performance.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Alexium International Group Limited (AJX) ORDINARY FULLY PAID |
Materials |
$22 |
Half Year Report and Accounts
|
26 Feb 2026 10:00AM |
$0.007 |
$0.007 |
fallen by
0%
|
|
AJX - Price-sensitive ASX Announcement
Full Release
Key Points
- Alexium International Group Limited focused on strategic initiatives.
- The company worked on enhancing product offerings and expanding market reach.
- Financial statements include profit and loss, balance sheets, and cash flow statements.
- Emphasis on research and development and market expansion activities.
- Efforts were made to optimize operations amid challenging market conditions.
- The aim was to strengthen the position in the specialty chemicals sector.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Acrux Limited (ACR) ORDINARY FULLY PAID |
Health Care |
$5 |
Notification of cessation of securities - ACR
|
26 Feb 2026 9:59AM |
$0.014 |
$0.011 |
fallen by
21.43%
|
|
| QBE Insurance Group Limited (QBE) ORDINARY FULLY PAID |
Financials |
$34,422 |
Application for quotation of securities - QBE
|
26 Feb 2026 9:59AM |
$21.890 |
$23.040 |
risen by
5.25%
|
|
| Novo Resources Corp. (NVO) CHESS DEPOSITARY INTERESTS 1:1 |
Materials |
$31 |
Proposed issue of securities - NVO
|
26 Feb 2026 9:59AM |
$0.130 |
$0.075 |
fallen by
42.31%
|
|
| Novo Resources Corp. (NVO) CHESS DEPOSITARY INTERESTS 1:1 |
Materials |
$31 |
Proposed issue of securities - NVO
|
26 Feb 2026 9:58AM |
$0.130 |
$0.075 |
fallen by
42.31%
|
|
| Clime Capital Limited (CAM) ORDINARY FULLY PAID |
Financials |
$100 |
Dividend/Distribution - CAM
|
26 Feb 2026 9:58AM |
$0.700 |
$0.705 |
risen by
0.71%
|
|
| Novo Resources Corp. (NVO) CHESS DEPOSITARY INTERESTS 1:1 |
Materials |
$31 |
Proposed issue of securities - NVO
|
26 Feb 2026 9:58AM |
$0.130 |
$0.075 |
fallen by
42.31%
|
|
| Novo Resources Corp. (NVO) CHESS DEPOSITARY INTERESTS 1:1 |
Materials |
$31 |
Proposed issue of securities - NVO
|
26 Feb 2026 9:58AM |
$0.130 |
$0.075 |
fallen by
42.31%
|
|
| Clinuvel Pharmaceuticals Limited (CUV) ORDINARY FULLY PAID |
Health Care |
$478 |
Half Year Results Presentation
|
26 Feb 2026 9:58AM |
$11.410 |
$9.470 |
fallen by
17%
|
|
CUV - Price-sensitive ASX Announcement
Full Release
Key Points
- Maintained underlying profitability with AUD 36.93 million in revenues.
- Profit after tax decreased by 26% to AUD 10.44 million.
- Focus on long-term safety with melanocortins and injectable peptides.
- Ongoing Phase III studies for vitiligo.
- Strategic preparation for U.S. vitiligo market expansion.
- Strong cash reserves of AUD 233 million for self-financing expansion.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Novo Resources Corp. (NVO) CHESS DEPOSITARY INTERESTS 1:1 |
Materials |
$31 |
Commitment Received for A$8.2m Placement
|
26 Feb 2026 9:58AM |
$0.130 |
$0.075 |
fallen by
42.31%
|
|
NVO - Price-sensitive ASX Announcement
Full Release
Key Points
- Firm commitments for A$8.2 million placement received.
- Placement conducted in two tranches; shareholder approval required for Tranche 2.
- Funds to support drilling and exploration in Western Australia.
- Northern Star Ltd. and a director to participate in Tranche 2.
- Options to be offered to CDI Placement participants, subject to approval.
- Planned drilling programs to focus on Wyloo, Balla Balla, and Teichman projects.
- Novo to resume ASX trading with settlement of Tranche 1 on 3 March 2026.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Thrive Tribe Technologies Limited (1TT) ORDINARY FULLY PAID |
Information Technology |
$2 |
Notification regarding unquoted securities - 1TT
|
26 Feb 2026 9:57AM |
$0.001 |
$0.001 |
fallen by
0%
|
|
| Cettire Limited (CTT) ORDINARY FULLY PAID |
Consumer Discretionary |
$74 |
H1 FY26 Results Presentation
|
26 Feb 2026 9:57AM |
$0.450 |
$0.195 |
fallen by
56.67%
|
|
CTT - Price-sensitive ASX Announcement
Full Release
Key Points
- Ex-USA sales revenue growth of 13%, highlighting market share gains.
- Disciplined marketing investments have reduced the rate of new customer acquisitions.
- Strong engagement with repeat customers, accounting for 69% of gross revenue.
- Adjusted EBITDA of $8.7 million, indicating a significant profitability turnaround.
- Cash balance of $61 million with no financial debt, showcasing financial resilience.
- Emerging Markets now make up 45% of gross revenues.
- Localization efforts included launching an Arabic platform for Middle East expansion.
- The luxury goods market is facing a decline, impacting demand, particularly in the US.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Estrella Resources Limited (ESR) ORDINARY FULLY PAID |
Materials |
$80 |
Ira Miri sample exceeds expectations ahead of completion
|
26 Feb 2026 9:56AM |
$0.032 |
$0.036 |
risen by
12.50%
|
|
ESR - Price-sensitive ASX Announcement
Full Release
Key Points
- Approximately 22,600 tonnes of manganese extracted.
- Extraction forms part of a 30,000-tonne market sample.
- High-grade ore extracted ahead of sale and shipment.
- Potential for significant project expansion identified.
- Port stockpile location approved by ANM.
- Successful extraction supports a Category A Mining Licence application.
- High workforce engagement and no lost-time injuries.
- Strong support from the Timor-Leste Government.
- Ore ready for international partner assessment.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Cettire Limited (CTT) ORDINARY FULLY PAID |
Consumer Discretionary |
$74 |
H1 FY26 Results ASX Announcement
|
26 Feb 2026 9:55AM |
$0.450 |
$0.195 |
fallen by
56.67%
|
|
CTT - Price-sensitive ASX Announcement
Full Release
Key Points
- Cettire reported H1 FY26 gross revenue of $505.7 million.
- Adjusted EBITDA for H1 FY26 was $8.7 million, marking a $20.5 million turnaround from H2 FY25.
- Sales in the US were significantly impacted by new trade policies, particularly the removal of the de minimis exemption.
- Revenue from regions outside the US grew by 13% year-on-year.
- The average order value increased by 17% due to higher US pricing.
- Reduction in marketing expenses by 42% led to a 12% decline in active customers.
- Repeat customers contributed to 69% of gross revenue.
- Emerging markets increased their share of gross revenue to 45%.
- Cettire launched an Arabic language capability and a flagship store on JD.com.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Clinuvel Pharmaceuticals Limited (CUV) ORDINARY FULLY PAID |
Health Care |
$478 |
CLINUVEL Record Revenues, Advances Strategic Expansion
|
26 Feb 2026 9:55AM |
$11.410 |
$9.470 |
fallen by
17%
|
|
CUV - Price-sensitive ASX Announcement
Full Release
Key Points
- Record revenues with a 4% increase in sales for the December half-year.
- Twentieth consecutive half-year profit.
- Expenses increased by 22%, impacting net profit after tax by 26%.
- Cash reserves increased to $233 million.
- Strategic focus on low-risk, non-dilutive growth.
- Preparing for expansion in vitiligo and NEURACTHEL® market.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Mont Royal Resources Limited (MRZ) ORDINARY FULLY PAID |
Materials |
$40 |
Mont Royal Receives Extension of Conditional Funding
|
26 Feb 2026 9:54AM |
$0.205 |
$0.210 |
risen by
2.44%
|
|
MRZ - Price-sensitive ASX Announcement
Full Release
Key Points
- Extension of conditional funding from Natural Resources Canada (NRCan) for Mont Royal's Ashram Project.
- Funding amounting to up to C$2.6 million from the Critical Minerals Infrastructure Fund.
- Development of Southern Road Access Strategy for enhanced logistics and transportation.
- The infrastructure supports Indigenous communities and other projects in Nunavik.
- The project involves a logistics chain from Ashram to Schefferville and further by rail and sea.
- Ashram Project contains one of the highest quality rare earth and fluorspar deposits globally.
- Conditional funding supports planning, baseline studies, pre-feasibility, and feasibility studies.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Clinuvel Pharmaceuticals Limited (CUV) ORDINARY FULLY PAID |
Health Care |
$478 |
Appendix 4D and Half Year Report
|
26 Feb 2026 9:54AM |
$11.410 |
$9.470 |
fallen by
17%
|
|
CUV - Price-sensitive ASX Announcement
Full Release
Key Points
- 10th consecutive half-year profit with strong NPBT and NPAT margins.
- Net assets increased by 3.4% over the past six months.
- Maintained a debt-free position for 21 consecutive years.
- Total revenues decreased by 6% to $40.56 million due to foreign exchange impacts.
- Expansion of the VALLAURIX RD&I Centre in Singapore.
- Advancement in clinical trials for SCENESSE® for treatments like vitiligo and porphyrias.
- Development of NEURACTHEL® for CNS disorders.
- Focus on PhotoCosmetics and controlled-release peptide formulations.
- Prioritization of long-term value creation and strategic capital allocation.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Farm Pride Foods Limited (FRM) ORDINARY FULLY PAID |
Consumer Staple |
$48 |
Appendix 4D and Half Year Financial Report
|
26 Feb 2026 9:54AM |
$0.240 |
$0.210 |
fallen by
12.50%
|
|
FRM - Price-sensitive ASX Announcement
Full Release
Key Points
- Net profit after tax for the period was $8.295 million.
- Revenue increased by 40.27% to $63.314 million.
- The company completed projects aimed at improving farm and processing efficiency.
- No dividends were declared for the period.
- Net assets increased to $51.294 million.
- Compliance with all debt covenants was maintained.
- Investments include a new standalone rearing farm in Victoria.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Neuren Pharmaceuticals Limited (NEU) ORDINARY FULLY PAID |
Health Care |
$1,617 |
Pause in Trading
|
26 Feb 2026 9:53AM |
$12.710 |
$12.790 |
risen by
0.63%
|
|
NEU - Price-sensitive ASX Announcement
Full Release
Key Points
- Neuren Pharmaceuticals Limited is listed with the security code NEU.
- A trading pause was announced for Neuren Pharmaceuticals Limited's securities.
- Further announcements from the company are anticipated.
- The announcement was made in compliance with ASX listings.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
Call 1300 880 160
Start a chat
Schedule a call
